search
Back to results

A Guided Self-determination Intervention Versus Attention Control for People With Type 2 Diabetes in Outpatient Clinics (OVERCOME)

Primary Purpose

Type 2 Diabetes

Status
Unknown status
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Guided self-determination
Personal support in goal-pursuing
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type 2 Diabetes

Eligibility Criteria

18 Years - 110 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • >18 years of age.
  • Diagnosed with type 2 diabetes ≥ 3 months according to the International Classification System of Diseases (ICD-11.2-11.9) [43].
  • Signed informed consent

Exclusion Criteria:

  • Pregnancy
  • Prior participation in GSD course(s) for the past two years
  • Lack of signed of informed consent

Sites / Locations

  • Anne Sophie MathiesenRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Guided self-determination

Personal support in goal-pursuing

Arm Description

3 to 5 one-hour digital or analogue guided self-determination sessions

Up to five personal goal pursuing support sessions

Outcomes

Primary Outcome Measures

diabetes distress
Assessed by the validated 20-item scale of diabetes-related distress burden, Problem Areas in Diabetes (PAID)

Secondary Outcome Measures

Depressive symptoms
Assessed by the Hospital Anxiety and Depression Scale (HADS)
Generic Quality of life: SF-36
Generic quality of life assessed by SF-36 The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability.
Adverse events not considered serious
Assessed by the Negative Effects questionnaire (NEQ-20) at 12-months follow-up. A higher score (0-80) indicate more adverse events related to the intervention.
diabetes distress
Assessed by the validated 20-item scale of diabetes-related distress burden, Problem Areas in Diabetes (PAID)

Full Information

First Posted
October 7, 2020
Last Updated
October 18, 2021
Sponsor
Rigshospitalet, Denmark
Collaborators
Odense University Hospital, Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT04601311
Brief Title
A Guided Self-determination Intervention Versus Attention Control for People With Type 2 Diabetes in Outpatient Clinics
Acronym
OVERCOME
Official Title
A Digitally Supported Guided Self-determination Intervention Versus Attention Control for People With Type 2 Diabetes in Outpatient Clinics - a Randomised Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Unknown status
Study Start Date
November 11, 2020 (Actual)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
Collaborators
Odense University Hospital, Copenhagen Trial Unit, Center for Clinical Intervention Research, Copenhagen University Hospital, Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Background In management of type 2 diabetes, autonomy supporting interventions may be a prerequisite to achieve 'real life' patient engagement and more long-term improvement. Preliminary evidence has previously shown that the autonomy supporting intervention, guided self-determination method might have effect on HbA1c and diabetes distress in people with type 1 diabetes. However, previous trials were all rated as high risk of bias and did not assess potential harm of the the intervention. Thus, in the current trial, the objective is to investigate the benefits and harms of guided self-determination interventions versus an attention control group intervention in adults with type 2 diabetes. Methods/design The trial planned is a randomised, pragmatic, investigator-initiated, dual-centre, parallel group, clinical superiority trial of guided self-determination intervention versus an attention control group for people diagnosed with type 2 diabetes in outpatient clinics. The participants (n=224) will be recruited from the department of Endocrinology at a University hospital of Copenhagen, the Capital Region of Denmark and from Steno Diabetes Center Odense, University hospital in the Southern Region of Denmark. The experimental stepped-care intervention will consist of 3-5 analogue or digitally provided guided self-determination sessions lasting up to one hour with a guided self-determination facilitator. The attention control group will receive similar number of sessions lasting up to one hour with a communication trained healthcare professional provided face-to-face, digitally, or over telephone.This trial protocol is guided by the SPIRIT and CONSORT guidelines. Participants will be included if they have type 2 diabetes, > 18 years old, and, are not pregnant. Participants will be assessed before randomisation, at 5- and 12-months follow-up. The primary follow-up timepoint will be 12-months follow-up. The primary outcome will be diabetes distress. Secondary outcomes will be quality of life, depressive symptoms, and adverse events not considered serious. Exploratory outcome will be glycated haemoglobin, motivation, and serious adverse events. Data will be collected using REDCap. The analyses will be performed using the statistical programme Stata version 16.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Participants and treatment providers will not be blinded to the allocated trial intervention. The treatment providers are not involved in the analyses. All other medical personnel will be blinded by blinding of notes in the participant's electronic records. Outcome assessors and external statisticians at the Copenhagen Trial Unit will be blinded to the randomisation status of the participants. The statistical analyses will be conducted with the intervention groups coded as X and Y. The steering committee will write two abstracts while the blinding is intact, one assuming the experimental intervention group is X and the control intervention group is Y, and one assuming the opposite. After this, the code will be broken.
Allocation
Randomized
Enrollment
224 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Guided self-determination
Arm Type
Experimental
Arm Description
3 to 5 one-hour digital or analogue guided self-determination sessions
Arm Title
Personal support in goal-pursuing
Arm Type
Active Comparator
Arm Description
Up to five personal goal pursuing support sessions
Intervention Type
Behavioral
Intervention Name(s)
Guided self-determination
Intervention Description
Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'…. The goal is registered. Patients go through a guided self-determination intervention preparing themselves by completing reflection sheets, analogue or digital by patient's choice, and individually facilitated by a guided self-determination-certified nurse, face-to-face, over video or over telephone. Sessions scheduled every second week. Number of sessions 3-5 is decided at session 2. A relative may take part in one session completing an analogue reflection sheet as preparation. Participants continue usual care.
Intervention Type
Behavioral
Intervention Name(s)
Personal support in goal-pursuing
Intervention Description
Before randomisation, the participants are supported in formulating one personal value-clarifying goal: 'One thing I want to achieve in my life with diabetes within a year is'…. The goal is registered. Patients receive personal goal pursuing support up to five sessions, lasting up to one hour with a communication trained healthcare professional following up on the goal, face-to-face, digitally, or over telephone. The sessions are scheduled every second week. A relative may take part in one session. Participants continue usual care.
Primary Outcome Measure Information:
Title
diabetes distress
Description
Assessed by the validated 20-item scale of diabetes-related distress burden, Problem Areas in Diabetes (PAID)
Time Frame
The Problem area in diabetes (PAID) will be measured at 12-months follow-up. A higher score on the scale (0-100) indicate higher diabetes distress
Secondary Outcome Measure Information:
Title
Depressive symptoms
Description
Assessed by the Hospital Anxiety and Depression Scale (HADS)
Time Frame
Hospital anxiety and depression scale (HADS) will be measured at 12-months follow-up. A higher score on the scale (0-42) indicate higher anxiety and depression
Title
Generic Quality of life: SF-36
Description
Generic quality of life assessed by SF-36 The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability.
Time Frame
SF-36 will be measured at baseline 12-months follow-up.
Title
Adverse events not considered serious
Description
Assessed by the Negative Effects questionnaire (NEQ-20) at 12-months follow-up. A higher score (0-80) indicate more adverse events related to the intervention.
Time Frame
12-months follow-up
Title
diabetes distress
Description
Assessed by the validated 20-item scale of diabetes-related distress burden, Problem Areas in Diabetes (PAID)
Time Frame
Problem areas in diabetes (PAID) will be measured at 5 months follow-up. A higher score on the scale (0-100) indicate higher diabetes distress
Other Pre-specified Outcome Measures:
Title
Type of motivation (autonomous/external), controlled (external) or resigned (amotivated) regarding diabetes self-care practices
Description
Assessed by the Treatment self-regulation Questionnaire
Time Frame
Assessed at 12-months follow-up.Autonomous motivation indicated by higher treatment self-regulation Questionnaire (TSRQ)-scores on autonomy (8-56) or autonomy-index (autonomy (8-56) minus control(9-63) or lower TSRQ-scores on amotivation (4-28)
Title
HbA1c
Description
Assessed from the participants' record. A higher value indicate poorer glycaemic control
Time Frame
Assessed at baseline and 12-months follow-up.
Title
Proportion of participants with one or more serious adverse events in the intervention period
Description
Defined according to the ICH-GCP definition, as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolonging of existing hospitalization and resulted in persistent or significant disability or jeopardized the patient
Time Frame
12-months follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
110 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: >18 years of age. Diagnosed with type 2 diabetes ≥ 3 months according to the International Classification System of Diseases (ICD-11.2-11.9) [43]. Signed informed consent Exclusion Criteria: Pregnancy Prior participation in GSD course(s) for the past two years Lack of signed of informed consent
Facility Information:
Facility Name
Anne Sophie Mathiesen
City
Copenhagen
ZIP/Postal Code
2200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Sophie Mathiesen, Post doc
Phone
+45 27908669
Email
anne.sophie.mathiesen@regionh.dk

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the International Committee of Medical Journal Editors (ICMJE), a detailed data sharing plan is a requirement. We adhere to the requirements with the following statements: Depersonalised individual patient data will be made available to increase transparancy and use of data. Immediately following publication the Trial Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, Analytic Code will be made available through a link for anyone who wishes to a access data. There will be no end date for this access.
IPD Sharing Time Frame
Immediately following publication the Trial Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, Analytic Code will be made available through a link for anyone who wishes to a access data
IPD Sharing Access Criteria
There will be no end date for this access.
Citations:
PubMed Identifier
34949603
Citation
Mathiesen AS, Zoffmann V, Skytte TB, Jakobsen JC, Gluud C, Lindschou J, Rasmussen B, Marqvorsen E, Thomsen T, Rothmann M. Guided self-determination intervention versus attention control for people with type 2 diabetes in outpatient clinics: a protocol for a randomised clinical trial. BMJ Open. 2021 Dec 23;11(12):e047037. doi: 10.1136/bmjopen-2020-047037.
Results Reference
derived

Learn more about this trial

A Guided Self-determination Intervention Versus Attention Control for People With Type 2 Diabetes in Outpatient Clinics

We'll reach out to this number within 24 hrs